Pfizer immune-oncology leader joins Aduro Biotech as new CMO

pharmafile | April 23, 2019 | News story | Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology 

Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, just three months after the firm laid of more than a third of its workforce, as it refocused its efforts on developing treatments for cancer.

Dr Nuyten joins the firm just a few months after the California-headquartered company announced it would be laying off 37% of its workforce, as the firm set the reset button and decided it would focus on a handful of lead programmes looking at the STING and APRIL pathways in treatments for cancer.

“Dimitry’s expertise as a radiation oncologist specializing in cancer biology and his experience leading immuno-oncology clinical strategy and development will be instrumental to Aduro,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro.

“We are extremely pleased to welcome Dimitry as we prepare to broaden our development plans for STING agonist ADU-S100 and initiate our first in human study of anti-APRIL antibody BION-1301 in IgA nephropathy.”

Dr Nuyten joins Aduro from his role as Vice President and Immuno-Oncology Clinical Development Leader at Pfizer. Prior to joining Pfizer Dr Nuyten spen five years at Bristol-Myers Squibb where he was responsible for the development of several early phase compounds in oncology.

Commenting on his own appointment, Dr Nuyten said: “I am excited to join Aduro and continue building the company’s leadership position in STING and APRIL biology. I look forward to collaborating with Aduro’s clinical team and our external partners to generate additional data while making a meaningful impact for patients.”

Louis Goss

Related Content

Genentech shares positive results from phase 3 trial for breast cancer treatment

Genentech, a member of the Roche Group, has announced positive results from the phase 3 …


First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase …

Evotec and Dewpoint Therapeutics enter strategic partnership

Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …

Latest content